ArticleClinical rheumatology2016
Drug prescribing trends in adults with rheumatoid arthritis: a population-based comparative study from 2005 to 2014.
Article in Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Differences in Cause-Specific Mortality in Patients With Rheumatoid Arthritis by Sex and Seropositivity.The Journal of rheumatology · 2025Article
- Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort.Annals of the rheumatic diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The aim of this study was to examine drug prescribing trends for patients with rheumatoid arthritis (RA) over recent years and compare them to matched non-RA subjects. Retrospective prescription data were examined from 2005 to 2014 in a population-based incidence cohort of patients with RA and comparable non-RA subjects. Drugs for or related to the treatment of RA were excluded. Comparisons between cohorts of percentages of patients with at least one prescription in a specific drug category/class were performed using Poisson regression models adjusted for age and sex. The study included 497 RA (71 % female) and 527 non-RA subjects (70 % female). The overall observed percentage of subjects who were prescribed at least one drug over the 10-year period was somewhat higher among the RA compared to non-RA subjects (relative risk [RR], 1.04; 95 % confidence interval [CI], 0.99, 1.08). Over the study period, both groups demonstrated significant increases in the percentages of patients with at least one prescription (age- and sex-adjusted 7 % increase over 10 years in RA, p < 0.001; 11 % increase in non-RA, p < 0.001). Drugs that were more common among RA than non-RA included gastrointestinal drugs, antimicrobials, calcium metabolism modifiers, thyroid hormone replacement therapy, tricyclic antidepressants, antiasthma/inhaled corticosteroids, proton pump inhibitors, contraceptives, antihypertensives, and some others. Prescription drugs that were less common in RA than non-RA were statins and other antilipemic drugs. Excluding drug prescriptions specifically for treatment of RA, there was a marked overall increase in prescriptions for drugs for both RA and non-RA cohorts over the study period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.